[go: up one dir, main page]

KR950032287A - 단백질 c의 분해를 저해하는 방법 - Google Patents

단백질 c의 분해를 저해하는 방법 Download PDF

Info

Publication number
KR950032287A
KR950032287A KR1019950000002A KR19950000002A KR950032287A KR 950032287 A KR950032287 A KR 950032287A KR 1019950000002 A KR1019950000002 A KR 1019950000002A KR 19950000002 A KR19950000002 A KR 19950000002A KR 950032287 A KR950032287 A KR 950032287A
Authority
KR
South Korea
Prior art keywords
apc
solution
activated protein
less
salt concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1019950000002A
Other languages
English (en)
Inventor
쥬니어 월터 프랜시스 프라우티
섹크닉 조세핀
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22650141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR950032287(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950032287A publication Critical patent/KR950032287A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 활성화된 단백질 C의 자동 분해를 저해하거나 최소화하는 방법에 관한 것이다. 본 발명은 활성화된 단백질 C를 낮은 pH, 예를 들어, 약 pH 6.3 내지 pH 6.4에서 정제하고/하거나 저장하는 과정을 수행하여 가장 잘 예시도니다. aPC(activated protein C)의 자동 분해는 aPC를 3M 우레아 (aPC 활성의 완전한 회복은 변성제의 제거후에 수득된다)중에서 aPC를 배양하거나 또는 aPC를 극단적인 염 농도에서 배양함으로써 또한 최소화 될 수 있다. 본 발명은 또한 aPC가 낮은 pH로, 변성제 중에, 또는 극단적인 염 농도로 유지된 aPC 제제를 포함한다.

Description

단백질 C의 분해를 저해하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 활성화된 단백질 C를 pH 약 6.3 내지 약 7.0의 용액중에 보존시킴을 포함하는, 상기 활성화된 단백질 C의 분해를 최소화하는 방법.
  2. 제1항에 있어서, 상기 용액의 염 농도가 약 0.050 M 미만이거나, 또는 약 0.40M 보다 높은 방법.
  3. 제2항에 있어서, 상기 용액의 염 농도가 약 0.050M 미만인 방법.
  4. 제2항에 있어서, 상기 용액의 염 농도가 약 0.010M 미만인 방법.
  5. 제2항에 있어서, 상기 용액 중의 염이 염화나트륨인 방법.
  6. 활성화된 단백질 C를 변성제를 함유하는 용액중에 보존시킴을 포함하는, 상기 활성화된 단백질 C의 분해를 최소화하는 방법.
  7. pH 약 6.3 내지 약 7.0의 용액중의 활성화된 단백질 C를 포함하는 안정한 혈전증 치료제.
  8. 제7항에 있어서, 약 0.050M 미만이거나, 또는 약 0.40M 보다 높은 농도의 염을 추가로 포함하는 제제.
  9. 제8항에 있어서, 상기 용액의 염 농도가 약 0.050M 미만인 제제.
  10. 제7항에 있어서, 상기 완충액이 트리스-아세테이트, 나트륨, 시트레이트, 시트레이트-글리신 및 인산 나트륨으로 이루어진 그룹으로부터 선택되는 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950000002A 1994-01-05 1995-01-03 단백질 c의 분해를 저해하는 방법 Abandoned KR950032287A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17783294A 1994-01-05 1994-01-05
US08/177,832 1994-01-05

Publications (1)

Publication Number Publication Date
KR950032287A true KR950032287A (ko) 1995-12-20

Family

ID=22650141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950000002A Abandoned KR950032287A (ko) 1994-01-05 1995-01-03 단백질 c의 분해를 저해하는 방법

Country Status (29)

Country Link
EP (2) EP1087011A3 (ko)
JP (1) JP3778588B2 (ko)
KR (1) KR950032287A (ko)
CN (1) CN1109891A (ko)
AT (1) ATE201045T1 (ko)
AU (1) AU1003195A (ko)
BR (1) BR9500017A (ko)
CA (1) CA2139468C (ko)
CO (1) CO4600680A1 (ko)
CZ (1) CZ1395A3 (ko)
DE (2) DE10299053I2 (ko)
DK (1) DK0662513T3 (ko)
ES (1) ES2156190T3 (ko)
FI (1) FI115635B (ko)
GR (1) GR3036277T3 (ko)
HU (1) HUT70465A (ko)
IL (1) IL112236A (ko)
LU (2) LU90992I2 (ko)
NL (1) NL300108I2 (ko)
NO (2) NO320157B1 (ko)
NZ (1) NZ270271A (ko)
PE (1) PE43995A1 (ko)
PL (1) PL180703B1 (ko)
PT (1) PT662513E (ko)
RU (1) RU2167936C2 (ko)
SI (1) SI0662513T1 (ko)
UA (1) UA39178C2 (ko)
YU (1) YU295A (ko)
ZA (1) ZA9514B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1557463A1 (en) * 1997-04-28 2005-07-27 Eli Lilly & Company Improved methods for processing activated protein C
EA004881B1 (ru) * 1997-04-28 2004-08-26 Эли Лилли Энд Компани Лиофилизированные композиции на основе рекомбинантного человеческого активированного протеина с и их применение
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CA2410567A1 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c

Also Published As

Publication number Publication date
IL112236A (en) 1999-12-31
DK0662513T3 (da) 2001-05-28
ATE201045T1 (de) 2001-05-15
NO2006006I1 (no) 2006-05-15
IL112236A0 (en) 1995-03-30
DE10299053I1 (de) 2003-05-22
JP3778588B2 (ja) 2006-05-24
FI950044A0 (fi) 1995-01-04
CA2139468C (en) 2007-08-21
ZA9514B (en) 1996-07-03
SI0662513T1 (en) 2001-10-31
RU95100178A (ru) 1997-03-27
PL306671A1 (en) 1995-07-10
CA2139468A1 (en) 1995-07-06
EP1087011A3 (en) 2002-02-06
NO320157B1 (no) 2005-11-07
LU90993I2 (fr) 2003-02-18
FI950044L (fi) 1995-07-06
JPH07206704A (ja) 1995-08-08
EP0662513B1 (en) 2001-05-09
NO950018L (no) 1995-07-06
UA39178C2 (uk) 2001-06-15
EP0662513A1 (en) 1995-07-12
PT662513E (pt) 2001-08-30
DE10299053I2 (de) 2004-04-01
FI115635B (fi) 2005-06-15
PL180703B1 (pl) 2001-03-30
EP1087011A2 (en) 2001-03-28
GR3036277T3 (en) 2001-10-31
CO4600680A1 (es) 1998-05-08
BR9500017A (pt) 1995-10-03
CZ1395A3 (en) 1995-07-12
RU2167936C2 (ru) 2001-05-27
HU9500021D0 (en) 1995-03-28
LU90992I2 (fr) 2003-02-18
PE43995A1 (es) 1995-12-15
DE69520844D1 (de) 2001-06-13
AU1003195A (en) 1995-07-13
NL300108I1 (nl) 2003-02-03
CN1109891A (zh) 1995-10-11
YU295A (sh) 1997-09-30
NO950018D0 (no) 1995-01-03
HUT70465A (en) 1995-10-30
DE69520844T2 (de) 2001-11-08
NZ270271A (en) 1996-07-26
NL300108I2 (nl) 2003-06-02
ES2156190T3 (es) 2001-06-16

Similar Documents

Publication Publication Date Title
ATE36457T1 (de) Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
ATE302216T1 (de) Verfahren zur aufreinigung des faktors viii
DE69030765D1 (de) Medien zur zellzucht und verfahren dazu
DE69004101D1 (de) Verfahren zur kristallisation von enzymen.
DK1329461T3 (da) Fremgangsmåde til fjernelse af humane serum-albumin-polymerer
KR950032287A (ko) 단백질 c의 분해를 저해하는 방법
US3818106A (en) Tenderization of meat with proteolytic enzymes
GB1472429A (en) Nitrohumic acid-based adsorbent
ES2174481T3 (es) Empleo de soluciones que contienen enzimas para la limpieza de tanques de fermentacion o de almacenamiento.
SE9403831D0 (sv) A storage stable water solution for infusion I
DE59108583D1 (de) Verfahren zur reaktivierung von denaturiertem protein
ATE139118T1 (de) Ribozymenhemmer
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19950103

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19991203

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19950103

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20020228

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee